Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy

Abstract Aim Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene express...

Full description

Bibliographic Details
Published in:	Cancer Medicine
Main Authors:	Sumit Sahni, Christopher Nahm, Mahsa S. Ahadi, Loretta Sioson, Sooin Byeon, Angela Chou, Sarah Maloney, Elizabeth Moon, Nick Pavlakis, Anthony J. Gill, Jaswinder Samra, Anubhav Mittal
Format:	Article
Language:	English
Published:	Wiley 2023-09-01
Subjects:	biomarkers chemotherapy response gene expression analysis neoadjuvant chemotherapy pancreatic ductal adenocarcinoma
Online Access:	https://doi.org/10.1002/cam4.6411

Similar Items

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
by: Nathalie B. Rasko, et al.
Published: (2025-01-01)

Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas
by: William A. Ziaziaris, et al.
Published: (2024-12-01)

Nomogram for the prediction of the prognosis of patients with triple-negative invasive ductal carcinoma of breast after neoadjuvant chemotherapy
by: Qiuyu Yang, et al.
Published: (2025-07-01)

The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
by: Eva L. Claassens, et al.
Published: (2025-04-01)

The prognostic differences between breast-conserving surgery and mastectomy in patients with invasive ductal carcinoma who achieved complete response following neoadjuvant chemotherapy: a propensity score matched analysis based on the SEER database
by: Cheng Xiao, et al.
Published: (2025-07-01)

Does concomitant ductal carcinoma in situ influence the prognostic outcome after neoadjuvant therapy in triple-negative invasive ductal carcinoma?
by: Sicheng Zhou, et al.
Published: (2025-03-01)

Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma
by: Luise Rupp, et al.
Published: (2024-04-01)

Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study
by: Zheng Li, et al.
Published: (2024-01-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status
by: Eunju Shin, et al.
Published: (2024-07-01)

Clinicopathological characteristics and survival analysis of different molecular subtypes of breast invasive ductal carcinoma achieving pathological complete response through neoadjuvant chemotherapy
by: Cheng Xiao, et al.
Published: (2024-09-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients Treated With Mastectomy: Indications for Treatment and Oncological Outcomes
by: Corrado Tinterri, et al.
Published: (2024-10-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
by: Freshte Foroughi, et al.
Published: (2024-12-01)

Advantages and advances in neoadjuvant therapy of pancreatic cancer
by: HU Binwei, SHEN Baiyong
Published: (2024-01-01)

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
by: Ryo Fujiwara, et al.
Published: (2015-08-01)

Total neoadjuvant therapy for rectal cancer: evidence and challenge
by: Suk-Hwan Lee
Published: (2023-08-01)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
by: Shigenori Ei, et al.
Published: (2023-09-01)

Study of feasibility and efficacy of neoadjuvant chemotherapy in cases of locally advanced breast cancer
by: Arun V Dawle, et al.
Published: (2015-01-01)

Cervical Mesonephric Adenocarcinoma Treated with Neoadjuvant Chemotherapy: A Case Report and a Literature Review
by: Hiroaki Ishida, et al.
Published: (2024-11-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
by: Tarik Sengoz, et al.
Published: (2023-04-01)

CHEST WALL RELAPSE OF DUCTAL CARCINOMA IN SITU AFTER MASTECTOMY: A CASE REPORT
by: Bektaş Kaya, et al.
Published: (2013-01-01)

Neoadjuvant chemotherapy in neonatal Wilms′ tumor
by: Ramesh K Reddy, et al.
Published: (2015-01-01)

Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single‐cell analysis
by: Sooin Byeon, et al.
Published: (2023-09-01)

Neoadjuvant chemotherapy in the treatment of rectal cancer without mesorectal fascia involvement but with negative prognostic factors
by: S. O. Kochkina, et al.
Published: (2020-08-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological Surgery
by: Masanori Tokunaga, et al.
Published: (2023-11-01)

Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study
by: Hua-Long Zheng, et al.
Published: (2025-12-01)

Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery
by: Shu Oikawa, et al.
Published: (2025-10-01)

Treatment Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Propensity Score Overlap Weighting Analysis of a Multicenter Taiwanese Cohort
by: Yi-Ju Chou, et al.
Published: (2025-11-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with IfosfamideDoxorubicin for Osteosarcoma
by: Mozhgan Aalam Samimi, et al.
Published: (2014-03-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

Neoadjuvant systemic therapy for patients with gastric cancer: Current concepts and outcomes
by: Fatih Selcukbiricik, et al.
Published: (2016-01-01)

Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer
by: Madison L. Conces, et al.
Published: (2024-01-01)

Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial
by: Guozhen Yang, et al.
Published: (2023-06-01)

Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis
by: Xuan Li, et al.
Published: (2017-11-01)

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
by: Yu. S. Sidorenko, et al.
Published: (2014-08-01)